Presage eyes drug, diagnostic development with fresh cash from Celgene

Presage Biosciences was started in 2008 to help pharmaceutical companies determine early in drug discovery whether therapeutic candidates would work in specific tumor types, but with cash from its second research collaboration the company will be able to pursue its own drug and diagnostic development aspirations.

Presage Biosciences was started in 2008 to help pharmaceutical companies determine early in drug discovery whether therapeutic candidates would work in specific tumor types, but with cash from its second research collaboration the company will be able to pursue its own drug and diagnostic development aspirations.

Seattle, Washington-based Presage received a $5 million upfront payment and $8 million equity investment from Celgene under a strategic collaboration...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category